Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etavopivat - Forma therapeutics

Next Previous
X
Search
Drug Profile

Etavopivat - Forma therapeutics

Alternative Names: FT-4202; NN 7535; NN-7536; NN7535 – Etavopivat in SCD; NN7535 – Etavopivat in Sickle cell disease; NN7536 – Etavopivat in Beta thalassemia

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FORMA Therapeutics
  • Class Antianaemics; Small molecules
  • Mechanism of Action Pyruvate kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia
  • Phase II Myelodysplastic syndromes; Thalassaemia

Most Recent Events

  • 28 May 2024 Novo Nordisk initiates a pharmacokinetic phase I trial for sickle cell anemia and thalassemia (In volunteers) in the US (NCT06433661)
  • 28 May 2024 Novo Nordisk plans to initiate a pharmacokinetic phase I trial for sickle cell anemia and thalassemia (In volunteers) in the US (NCT06433661)
  • 16 May 2024 Forma Therapeutics initiates a Phase I trial for Sickle cell disease in the US (PO) (NCT05725902)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top